Showing results (21-30 of 67) with videos related to

Sort By:
Pageof 7
Internal Medicine Journal|June 20, 2025
A single-institution study of allograft outcomes for chronic lymphocytic leukaemia over 20 yearsRory Bennett, Thomas Frawley, Philip A Thompson, et al.
Cancer|February 8, 2017
Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinibPreetesh Jain, Philip A Thompson, Michael Keating, et al.
Leukemia & Lymphoma|July 27, 2025
Real-world utilization of Bruton tyrosine kinase inhibitors in relapsed/refractory chronic lymphocytic leukemia in AustraliaStephen P Mulligan, Philip A Thompson, Joel Wight, et al.
Bioorganic & Medicinal Chemistry Letters|March 3, 2009
Selective inhibition of Pfmrk, a Plasmodium falciparum CDK, by antimalarial 1,3-diaryl-2-propenonesJeanne A Geyer, Susan M Keenan, Cassandra L Woodard, et al.
Blood Advances|March 25, 2026
NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapyAlexandre Bazinet, Alessandra Ferrajoli, Nitin Jain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2016
Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic LeukemiaPreetesh Jain, Michael J Keating, William G Wierda, et al.
Blood|August 18, 2023
Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-upPhilip A Thompson, Alexandre Bazinet, William G Wierda, et al.
Leukemia & Lymphoma|November 6, 2012
Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myelomaNicole Wong Doo, Philip A Thompson, H Miles Prince, et al.
Cancer|November 21, 2015
β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemiaPhilip A Thompson, Susan M O'Brien, Lianchun Xiao, et al.
Blood Cancer Journal|March 14, 2021
The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of actionRong Chen, Jennifer Tsai, Philip A Thompson, et al.
Pageof 7